Mycophenolate mofetil for the management of autoimmune bullous diseases

Immunol Allergy Clin North Am. 2012 May;32(2):309-15, vii. doi: 10.1016/j.iac.2012.04.010. Epub 2012 Apr 18.

Abstract

Immunosuppressive agents such as azathioprine, cyclophosphamide, and mycophenolate mofetil (MMF) are now widely used in the treatment of autoimmune bullous diseases. This article reviews the use of MMF for the treatment of several bullous conditions, and assesses the evidence gathered from clinical trials and case series. According to numerous case series, MMF could be of value in treating refractory disease. The few randomized clinical trials conducted to date of patients with pemphigus and bullous pemphigoid report a similar efficacy for MMF to other immunosuppressants.

Publication types

  • Review

MeSH terms

  • Animals
  • Anti-Inflammatory Agents / therapeutic use*
  • Autoimmune Diseases / drug therapy*
  • Autoimmune Diseases / immunology
  • Evidence-Based Medicine
  • Humans
  • Immunosuppression Therapy
  • Mycophenolic Acid / analogs & derivatives*
  • Mycophenolic Acid / chemistry
  • Mycophenolic Acid / therapeutic use
  • Randomized Controlled Trials as Topic
  • Skin Diseases, Vesiculobullous / drug therapy*
  • Skin Diseases, Vesiculobullous / immunology

Substances

  • Anti-Inflammatory Agents
  • Mycophenolic Acid